FOOD SUPPLEMENTS

Do multimodal supplement stacks outperform single ingredients in human trials?

How clinical researchers evaluate targeted food supplements alongside exercise, why combining compounds creates pharmacokinetic trade-offs, and which blood and functional markers verify an effect.

LetsGo Editorial · LetsGo Editorial · 26 October 2026 · 12 min read

Academic longevity trials are shifting from testing isolated molecules to evaluating multimodal guides that combine targeted food supplements, structured exercise, and health coaching—exposing a wide gap between controlled feasibility studies and commercial multi-ingredient stacks.

Clinical trials evaluating healthspan interventions for adults aged 50 to 80 increasingly test multiple interventions simultaneously rather than relying on a single capsule in isolation. Modern guides—such as 8-week feasibility studies designed for healthspan competitions—combine targeted food supplements with resistance training, aerobic conditioning, and structured coaching. Alongside these multimodal feasibility trials, separate human randomized controlled trials (RCTs) test isolated geroprotective candidates, such as sirtuin-6 (SIRT6) activators in pre-frail older adults, to isolate molecular effects on genomic stability and systemic inflammation. For an adult evaluating food supplements outside a university trial, this creates an attribution problem. Commercial brands frequently cite the launch of academic multimodal programmes as validation for multi-ingredient consumer stacks. In clinical research, however, a feasibility trial only tests whether participants can adhere to a complex schedule and whether starting point and follow-up measurements can be collected reliably; without factorial comparator arms, it does not establish that the supplement component drove the physiological outcome. Evaluating food supplements requires separating nutrient repletion from experimental pathway modulation, checking whether multi-ingredient combinations create antagonistic signalling in human tissue, and tracking objective biomarkers before and after any intervention.

What it is

Food supplements (or dietary supplements) are concentrated sources of micronutrients, amino acids, fatty acids, or botanical bioactives marketed in measured forms such as capsules, tablets, powders, or liquids to produce a nutritional or physiological effect. Unlike prescription pharmaceuticals, food supplements do not require pre-market phase III efficacy trials demonstrating disease modification in humans prior to retail sale. In clinical medicine and exercise physiology, food supplements divide into three functional tiers: 1. Targeted Micronutrient Repletion: Compounds used to correct a documented laboratory insufficiency or deficiency, restoring normal enzymatic kinetics and receptor signalling. Examples include cholecalciferol (vitamin D3), cobalamin (vitamin B12), folate, magnesium, and iron. 2. Ergogenic and Structural Substrates: Compounds with established human bioavailability that supply rate-limiting substrates for tissue synthesis, membrane integrity, or bioenergetics. Examples include creatine monohydrate (which saturates intramuscular phosphocreatine pools), marine omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA], which incorporate into phospholipid cell membranes), and dietary inorganic nitrates. 3. Experimental Pathway Modulators (Geroprotectors): Non-essential molecules intended to alter nutrient-sensing, DNA-repair, or cellular senescence pathways. Examples include nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)

aimed at the salvage pathway of nicotinamide adenine dinucleotide (NAD+), urolithin A aimed at mitophagy, and specialized botanical or synthetic polysaccharides designed to activate sirtuin enzymes such as SIRT1 or SIRT6. Academic trial centres study the third tier either as standalone investigational products in targeted cohorts (such as pre-frail older adults) or bundled inside multimodal programmes that simultaneously prescribe resistance training, aerobic exercise, and nutritional coaching. A feasibility study of an 8-week multimodal programme evaluates recruitment rates, compliance, and adverse events to inform larger trials; it does not validate commercial multi-ingredient stacks.

Why it is used

Age-related declines in gastrointestinal absorption, cutaneous cholecalciferol synthesis, and cellular NAD+ pools drive the clinical use of food supplements to correct measurable nutritional deficits and target the molecular hallmarks of aging. With advancing age, hypochlorhydria and altered enteric transport reduce the absorption of vitamin B12, iron, and calcium, while declining energy intake can create subclinical micronutrient deficits even when body mass remains stable. At the intracellular level, human and animal tissue studies demonstrate age-associated declines in NAD+ availability, reduced mitochondrial oxidative phosphorylation capacity, impaired autophagic flux, and diminished activity of NAD+-dependent deacetylases (sirtuins). Specifically, SIRT6 is a chromatin-associated nuclear protein that catalyzes both histone deacetylation (removing acetyl groups from histone H3 at lysines 9 and 56, H3K9ac and H3K56ac) and mono-ADP-ribosylation. In preclinical mouse and human cell-line models, SIRT6 promotes DNA double-strand break repair via poly(ADP-ribose) polymerase 1 (PARP1) activation, suppresses nuclear factor kappa B (NF-kB) pro-inflammatory transcription, and maintains telomeric chromatin structure. Because genetic overexpression of SIRT6 extends median and maximum lifespan in male mice and preserves hepatic gluconeogenic and glycolytic balance, human clinical trials are testing whether oral SIRT6-activating compounds can improve physical performance and lower inflammatory cytokines in pre-frail older adults. At present, the longevity mechanisms of SIRT6 activation are demonstrated only in rodents and cell culture; no reliable clinical effect size exists in humans. Multimodal trials combine supplements with structured exercise because isolated geroprotector trials in humans have frequently failed to alter functional clinical endpoints. The mechanistic hypothesis behind multimodal guides is that supplying a metabolic cofactor (such as an NAD+ precursor or mitochondrial substrate) requires concurrent mechanical and metabolic demand in skeletal muscle and vascular endothelium—generated via resistance and aerobic training—to increase energy turnover and translate biochemical availability into tissue remodeling.

How it helps

Oral bioavailability, first-pass hepatic extraction, active cellular transport, and the absence of antagonistic signalling determine whether a food supplement alters human physiology. Established Human Mechanisms and Effect Sizes: - Marine Omega-3 Fatty Acids (EPA and DHA): Incorporate into cardiomyocyte and endothelial phospholipid membranes, competing with arachidonic acid in cyclooxygenase and lipoxygenase pathways to reduce pro-inflammatory eicosanoids and inhibit hepatic diacylglycerol acyltransferase, decreasing very-low-density lipoprotein (VLDL) synthesis. In meta-analyses of human RCTs involving thousands of adults with hypertriglyceridemia over 8 to 24 weeks, purified supplemental and prescription omega-3s lower fasting serum triglycerides by 15% to 30%. - Creatine Monohydrate: Enters skeletal muscle myocytes via the sodium- and chloride-dependent creatine transporter (SLC6A8), elevating intracellular phosphocreatine stores to accelerate adenosine triphosphate (ATP) resynthesis via the creatine kinase reaction during high-intensity contractions. Meta-analyses of human RCTs in adults aged 50 to 80 (typically lasting 12 to 24 weeks with 20 to 100 participants per trial) demonstrate that creatine combined with progressive resistance training increases lean body mass by roughly 1.3 kg and significantly increases upper- and lower-body one-repetition maximum

(1-RM) strength compared to resistance training with placebo. - Psyllium Husk (Soluble Viscous Fibre): Forms a viscous gel in the small intestine that binds bile acids, preventing enterohepatic reabsorption in the terminal ileum and upregulating hepatic cholesterol 7-alpha-hydroxylase (CYP7A1) to draw circulating low-density lipoprotein (LDL) cholesterol into de novo bile acid synthesis. Meta-analyses of human RCTs lasting 4 to 24 weeks show reductions in LDL cholesterol and apolipoprotein B (ApoB) of roughly 5% to 10% in adults with normal to mildly elevated lipids. Emerging Human Evidence and The Biomarker-Outcome Disconnect: - NAD+ Precursors (NR and NMN): NAD+ serves as an obligatory co-substrate for sirtuins (SIRT1–SIRT7), PARPs, and cyclic ADP-ribose synthases (CD38). In human RCTs lasting 4 to 12 weeks in middle-aged and older adults (sample sizes of 30 to 140), oral NR and NMN consistently elevate whole-blood and peripheral blood mononuclear cell (PBMC) NAD+ concentrations by 40% to 150%. Despite this hematologic rise, skeletal muscle biopsies in these trials rarely show an increase in steady-state intramuscular NAD+, and meta-analyses show no consistent improvements in hyperinsulinemic-euglycemic clamp insulin sensitivity, VO2max, or muscle mitochondrial respiratory capacity. Isotope-tracing studies in rodents and pharmacokinetic data in humans indicate that oral NR and NMN undergo extensive first-pass cleavage by brush-border CD38 and gut microbiota into nicotinamide and nicotinic acid; excess hepatic nicotinamide is then methylated by nicotinamide N-methyltransferase (NNMT) into N-methylnicotinamide and excreted in urine before reaching peripheral skeletal muscle in quantities sufficient to alter bioenergetics. Antagonistic Interactions in Multimodal Stacks: Combining multiple supplements with exercise can produce antagonistic signalling in human tissue. During aerobic and resistance training, transient bursts of reactive oxygen species (ROS) generated by mitochondrial electron transport chain complexes I and III and nicotinamide adenine dinucleotide phosphate (NADPH) oxidases act as obligatory second messengers in human skeletal muscle. These ROS bursts activate AMP-activated protein kinase (AMPK) and p38 mitogen-activated protein kinase (p38 MAPK), which phosphorylate and upregulate peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha)—driving mitochondrial biogenesis—and induce endogenous antioxidant enzymes including superoxide dismutase (SOD1/SOD2) and glutathione peroxidase. In human RCTs (lasting 4 to 12 weeks in cohorts of 20 to 60 young and older adults), co-administering high intakes of exogenous direct antioxidants (vitamins C and E) or high-concentration resveratrol alongside endurance or high-intensity interval training blunted the exercise-induced rise in skeletal muscle PGC-1alpha mRNA, prevented exercise-mediated improvements in whole-body insulin sensitivity, and attenuated gains in VO2max and vascular endothelial function compared to exercise with placebo. Taking an unvalidated multi-ingredient stack containing concentrated polyphenols and direct antioxidants alongside a training programme quenches the hormetic ROS signal required for cellular adaptation.

Who should try it

Targeted supplementation is indicated for adults who use starting point blood panels and functional testing to identify specific micronutrient deficits or physiological bottlenecks, rather than consuming broad multi-ingredient stacks based on preclinical longevity claims. Populations with Established Benefit: - Adults with laboratory-confirmed micronutrient deficiencies: Individuals presenting with low serum 25-hydroxyvitamin D [25(OH)D], elevated plasma homocysteine or methylmalonic acid coupled with low serum vitamin B12 or folate, low serum ferritin, or low red blood cell (RBC) magnesium. - Adults aged 40 and older performing structured resistance training: Individuals aiming to preserve or increase appendicular skeletal muscle mass and strength using substrates with reproducible human RCT effect sizes, such as creatine monohydrate and dietary protein. - Adults addressing specific cardiometabolic lipid targets: Individuals with mildly elevated ApoB or fasting triglycerides who are pairing dietary modification with viscous soluble fibre or purified EPA/DHA under clinical monitoring. Trade-offs, Contraindications, and Opportunity Costs: - Cytochrome P450 and Transporter Interactions: Concentrated botanical extracts, curcuminoids, quercetin, resveratrol, berberine, and piperine (frequently added to commercial stacks to inhibit glucuronidation) inhibit hepatic cytochrome P450

enzymes—specifically CYP3A4, CYP2C9, and CYP2D6—as well as intestinal P-glycoprotein (ABCB1) efflux pumps. In human pharmacokinetic studies, this inhibition elevates plasma area-under-the-curve (AUC) concentrations of statins, direct oral anticoagulants (DOACs), calcium channel blockers, and calcineurin inhibitors, increasing toxicity risks. - Hepatotoxicity and Adulteration: Surveillance data from clinical hepatology registries document idiosyncratic drug-induced liver injury (DILI), marked by elevations in serum aminotransferases, linked to concentrated green tea catechins (epigallocatechin gallate [EGCG]), ashwagandha, Garcinia cambogia, and multi-ingredient botanical blends. Independent mass-spectrometry audits of retail supplements also identify heavy metal contamination (lead, arsenic, cadmium) and unlabelled pharmaceutical adulterants. - Antiplatelet and Bleeding Risks: High-intake marine omega-3 fatty acids, ginkgo biloba, concentrated garlic extracts, and vitamin E inhibit thromboxane A2 synthesis or platelet aggregation; these compounds are contraindicated prior to surgical procedures or alongside prescription antiplatelet and anticoagulant regimens. - Financial and Attribution Opportunity Cost: Commercial multi-ingredient longevity stacks frequently cost $150 to $400 per month—exceeding the cost of serial laboratory panels or supervised exercise coaching—while destroying clinical attribution. Initiating six compounds simultaneously makes it impossible to determine which molecule caused an adverse event (such as gastrointestinal distress, insomnia, or elevated liver enzymes) or a biomarker shift.

Measurements that show improvement

Serial biomarker and functional testing over an 8- to 12-week window—modifying only a single variable at a time—is the clinical standard for verifying whether a food supplement produces a physiological effect in an individual. If a compound fails to move its target metric within its established pharmacokinetic and tissue-turnover window, it should be discontinued. Blood Biomarkers: - Micronutrient Status Markers: - Serum 25(OH)D: Tracks cholecalciferol repletion; an increase from deficient levels (<20 ng/mL or <50 nmol/L) into the target sufficiency range (30–50 ng/mL or 75–125 nmol/L) over 8 to 12 weeks confirms intestinal absorption and hepatic 25-hydroxylation. - Serum Vitamin B12, Methylmalonic Acid (MMA), and Plasma Homocysteine: Functional intracellular B-vitamin repletion is verified when elevated MMA and homocysteine decline into reference ranges within 6 to 8 weeks. - Erythrocyte Omega-3 Index (EPA + DHA as a percentage of total red blood cell fatty acids): Reflects phospholipid membrane incorporation over an erythrocyte lifespan of 90 to 120 days; an upward shift from <4% toward >8% confirms tissue saturation. - Cardiometabolic and Inflammatory Markers: - Apolipoprotein B (ApoB) and Fasting Triglycerides: A 5% to 10% reduction in ApoB (with viscous soluble fibre) or a 15% to 30% reduction in fasting triglycerides (with purified EPA/DHA) over 8 to 12 weeks verifies lipid-lowering efficacy. - Fasting Insulin and HbA1c: Reductions in fasting insulin and HbA1c over 12 weeks indicate improved glycemic control. Conversely, high-intake nicotinic acid (niacin) or certain multi-ingredient stacks can impair beta-cell sensitivity and hepatic glucose output, increasing fasting glucose and fasting insulin. - High-sensitivity C-reactive protein (hs-CRP): Measures systemic IL-6–driven hepatic acute-phase inflammation; a sustained reduction below 1.0 mg/L (measured twice, two weeks apart, in the absence of acute infection) indicates reduced vascular inflammation. - Hepatic and Renal Safety Markers: - Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), and Gamma-Glutamyl Transferase (GGT): Must remain stable within starting point reference intervals; any rise exceeding 1.5 to 2 times the individual starting point 4 to 8 weeks after introducing a botanical extract or pathway modulator warrants immediate discontinuation. - Serum Cystatin C (with Cystatin C–based eGFR): Because oral creatine monohydrate undergoes non-enzymatic cyclization to creatinine at a rate of roughly 1.7% per day, creatine supplementation elevates serum creatinine and artificially depresses creatinine-based estimated glomerular filtration rate (eGFR). Serum Cystatin C is filtered freely by the glomerulus and is unaffected by dietary creatine or skeletal muscle mass, providing an accurate assessment of renal filtration. Functional and Physiological Markers: - VO2max and Ventilatory Thresholds: Measured via cardiopulmonary exercise testing (CPET) or validated submaximal field tests over 8 to 16 weeks. An increase in VO2max

(mL/kg/min) and Zone 2 power output confirms cardiorespiratory adaptation and verifies that a concurrent supplement regimen is not blunting mitochondrial biogenesis. - Handgrip Strength and Appendicular Skeletal Muscle Mass (ASMM): Measured via calibrated hand dynamometry (in kg) and dual-energy X-ray absorptiometry (DXA) over 12 to 24 weeks to quantify the anabolic synergy of ergogenic substrates paired with resistance training. - Resting Heart Rate (RHR), Nocturnal Heart Rate Variability (HRV, measured as RMSSD in ms), and Sleep Onset Latency: Tracked via validated photoplethysmography or electrocardiography wearables over a 14-day rolling starting point. An increase in RHR of >3–5 bpm, a sustained drop in nocturnal RMSSD, or prolonged sleep onset latency after introducing a supplement signals sympathetic activation or disturbed sleep architecture. - Composite Biological Age Algorithms: Phenotypic blood clocks (incorporating albumin, creatinine, glucose, hs-CRP, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and chronological age) and DNA methylation clocks must be deconstructed into their individual clinical analytes before attributing score changes to a supplement.

Products and services

These LetsGo products and services sit next to this subject. They are not a prescription. A link is not evidence that the product causes the change discussed above. - [LetsGo supplement shelf](/supplements) — Bottles LetsGo stocks for members. Read the label before the first order. A link is not a dose. - [LetsGo Academy](/academy) — The teaching track for coaches who use these explainers with members.

Practical takeaways

- Correct laboratory-confirmed micronutrient deficiencies—specifically serum 25(OH)D below 30 ng/mL, elevated homocysteine or methylmalonic acid with low vitamin B12, or an erythrocyte Omega-3 Index below 8%—and re-test at 8 to 12 weeks before introducing experimental pathway modulators.
- Introduce only one new food supplement at a time while holding exercise volume and diet constant for an 8- to 12-week evaluation window; discontinue the compound if its target blood or functional marker does not improve by more than biological day-to-day variability.
- Measure hepatic enzymes (ALT, AST, ALP, GGT) and serum Cystatin C at starting point and 4 to 8 weeks after initiating any concentrated botanical extract or multi-ingredient supplement; stop the product immediately if ALT or AST rises above 1.5 times your starting point.
- Avoid ingesting exogenous direct antioxidants (high-concentration vitamin C, vitamin E, or resveratrol) within 4 hours before or after aerobic and resistance training sessions to preserve ROS-mediated AMPK and PGC-1alpha mitochondrial signalling.
- Select single-ingredient products bearing independent third-party batch certification (USP, NSF Certified for Sport, or Informed-Choice) to verify label potency and screen out heavy metals and unlabelled pharmaceutical adulterants.

Safety note

Food supplements can inhibit or induce hepatic cytochrome P450 enzymes and P-glycoprotein transporters, impair platelet aggregation, and cause idiosyncratic drug-induced liver injury. Cross-check every supplement ingredient against prescription medications with a physician or clinical pharmacist, discontinue non-essential supplements at least two weeks prior to any surgical procedure, and monitor liver enzymes (ALT, AST, ALP, GGT) and muscle-independent renal function (Cystatin C) when introducing new compounds.

Disclaimer

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Food supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional

before starting, stopping, or combining any dietary supplement or exercise programme, particularly if you have pre-existing medical conditions or take prescription medications.

Evaluating food supplements requires the same empirical rigor applied to prescription interventions: identifying a measurable physiological deficit or target, confirming that the proposed mechanism translates from rodent models to human tissue, and verifying that the compound does not blunt concurrent exercise adaptations or alter drug clearance via hepatic CYP450 pathways. While academic multimodal feasibility trials and isolated sirtuin studies continue to test experimental geroprotectors, adults achieve the most reliable clinical return by correcting documented micronutrient deficiencies, pairing single-ingredient ergogenic substrates that have established human RCT effect sizes with structured training, and auditing every intervention against serial blood and functional biomarkers.